Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Delcath Systems reported strong Q2 2025 financial results, with revenue reaching $24.2 million, a 20%+ increase quarter-over-quarter, driven by $22.5 million in U.S. HEPZATO sales. The company achieved net income of $2.7 million and positive adjusted EBITDA of $9.8 million, ending the quarter with $81 million in cash and no debt. While full-year revenue guidance was slightly adjusted to $93 million-$96 million due to a slower pace of new site activations (targeting 25-28 by year-end, down from 30), average treatments per center remain consistent at approximately two per month. Delcath also entered the NDRA/340B program, which will introduce a 10-15% reduction in average revenue per kit but is expected to enhance long-term market access. Crucially, the company is advancing its pipeline, with Phase II trials for liver-dominant metastatic colorectal cancer initiated and metastatic breast cancer enrollment planned for Q1 2026, aiming to expand HEPZATO's market beyond its current ultra-orphan indication and leverage its existing site footprint.

Analysis

Delcath Systems demonstrated significant commercial execution and achieved a key inflection point in its Q2 2025 results, reporting its first profitable quarter with a net income of $2.7 million and a positive operating cash flow of $7.3 million. Quarterly revenue grew over 20% sequentially to $24.2 million, driven by strong U.S. adoption of HEPZATO, which generated $22.5 million. The company's financial position has been solidified, ending the quarter with $81 million in cash, no debt, and confidence in maintaining positive cash flow through 2025. Management has adjusted full-year revenue guidance slightly to $93-$96 million and lowered its year-end active site target to 25-28 from 30, citing the inherent complexities and episodic pace of activating large academic medical centers for a novel procedure. However, this is partially offset by consistent treatment volumes at existing sites, averaging two procedures per month. A pivotal strategic development is the company's entry into the NDRA/340B drug pricing program, which, while creating a 10-15% headwind on average revenue per kit starting in Q3, is expected to improve long-term market access and volume by making the therapy more financially attractive to hospitals. Concurrently, Delcath is leveraging its current profitability to fund its pipeline, having initiated a Phase II trial in metastatic colorectal cancer and preparing for a metastatic breast cancer trial in Q1 2026, signaling a clear strategy to expand beyond its initial ultra-orphan indication into larger markets.

Key Decisions for Investors

• Investors should monitor the rate of new site activations in the second half of 2025, as this remains the primary variable impacting the achievement of the revised revenue guidance of $93-$96 million.
• Financial models must be adjusted for the third quarter onward to reflect a 10-15% reduction in average revenue per HEPZATO kit due to the 340B program, alongside a significant ramp in R&D expenses as new clinical trials commence.
• Attention should be focused on long-term catalysts, particularly the CHOPIN trial data presentation at the ESMO conference in October 2025, which could validate combination strategies with immunotherapies and de-risk the expansion into larger cancer indications.